Combined phentermine/fenfluramine administration enhances depletion of serotonin from central terminal fields

Synapse

Volumn 26, Issue 1, 1997, Pages 36-45

  Lew, Robert ^a   Weisenberg, Brian ^a   Vosmer, Georgetta ^a   Seiden, Lewis S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

neuronal degeneration; neurotoxicity; obesity; weight reduction

Indexed keywords

CARRIER PROTEIN; FENFLURAMINE; PHENTERMINE; SEROTONIN; SEROTONIN TRANSPORTER;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MEGADOSE; HIPPOCAMPUS; HYPOTHALAMUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; PARIETAL LOBE; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; WEIGHT REDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG COMBINATIONS; DRUG SYNERGISM; FENFLURAMINE; HYPOTHALAMUS; MALE; PHENTERMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 0030898124     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199705)26:1<36::AID-SYN4>3.0.CO;2-F     Document Type: Article

References (34)

1. Alvares, A.P., and Pratt, W.B. (1990) Pathways of drug metabolism. In: Principles of Drug Action: The Basis of Pharmacology, ed. W.B. Pratt and P. Taylor, Churchill Livingstone, New York, pp. 365-422.
2. Appel, N.M., Contrera, J.F., and De Souza, E.B. (1989) Fen selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: Evidence from immunocytochemical studies. J. Pharmacol. Exp. Ther., 249:928-943.
3. Appel, N.M., Mitchell, W.M., Contrera, J.F., and De Souza, E.B. (1990) Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: Assessment using quantitative autoradiography. Synapse, 6:33-44.
4. Atkinson, R.L., and Hubbard, V.S. (1994) Report on the NIH workshop on pharmacologic treatment of obesity. Am. J. Clin. Nutr., 60:153-156.
5. Bartholomew, G.A. (1977) Energy Metabolism. In: Animal Physiology: Principles and adaptations ed. M.S. Gordon MacMillan, New York pp 57-110.
6. Battaglia, G., Yeh, S.Y., and De, S.E.B. (1988) MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29:269-274.
7. [125]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse, 12:27-36.
8. Caccia, S., Ballabio, M., Guiso, G., Rocchetti, M., and Garattini, S. (1982) Species differences in the kinetics and metabolism of fenfluramine isomers. Arch. Int. Pharmacodyn., 258:15-28.
9. Craddock, D. (1976) Anorectic drugs: Use in general practice. Drugs, 11:378-393.
10. Freireich, E.J., Gehan, E.A., Rail, D.P., Schmidt, L.H., and Skipper, H.E. (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Cherother. Rep. 50:219-226.
11. Harvey, J.A., and McMaster, S.E. (1975) Fenfluramine: Evidence for a neurotoxic action on a long-term depletion of serotonin. Psychopharmacol. Commun., 1:217-228.
12. Harvey, J.A. and McMaster, S.E. (1977) Fenfluramine: Cumulative neurotoxicity after chronic treatment with low dosages in the rat. Commun. Psychopharmacol., 1:3-17.
13. Harvey, J.A., McMaster, S.E., and Fuller, R.W. (1977) Comparison between the neurotoxic and serotonin depleting effects of various halogenated derivatives of amphetamine in the rat. J. Pharmacol. Exp. Ther., 202:581-589.
14. Heffner, T.G., Hartman, J.A., and Seiden, L.S. (1980) A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13:453-456.
15. Hewitt, K.E., and Green, A.R. (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ("ecstasy") to rats. Neuropharmacology, 33:1589-1595.
16. Hoebel, B.C., Hernandez, L., Schwartz, D.H., Mark, G.P., and Hunter, G.A. (1989) Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann. N.Y. Acad. Sci., 575:171-191.
17. Kleven, M.S., and Seiden, L.S. (1989) D-, L- and DL-fenfluramine cause long-lasting depletions of serotonin in rat brain. Brain Res., 505:351-353.
18. Kleven, M.S., Schuster, C.R., and Seiden, L.S. (1988) Effect of depletion of brain serotonin by repeated fenfluramine on neurochemical and anorectic effects of acute fenfluramine. J. Pharmacol. Exp. Ther. 246:822-828.
19. Kleven, M.S., Woolverton, W.L., and Seiden, L.S. (1991) Evaluation of potential neurotoxic effects of amphetamine-related anorectic agents on brain serotonin and dopamine in the rat. Proc. Soc. Neurosci., 17:1488.
20. Molliver, D.C., and Molliver, M.E. (1990) Anatomic evidence for a neurotoxic effect of (±)-fenfluramine upon serotonergic projections in the rat. Brain Res., 511:165-168.
21. Munson, P.J., and Rodbard, D. (1980) LIGAND: A versatile approach for characterization of ligand-binding systems. Anal. Biochem., 107:220-239.
22. Musch, A. (1996) Dose-time-effect relationships. In: Toxicology: Principles and Applications. R.J.M. Niesink, J. de. Vries, and M.A. Hollinger, eds. CRC Press, Boca Raton, New York, London, and Tokyo, pp 187-237.
23. Roth, B.L. (1994) Multiple serotonin receptors: Clinical and experimental aspects. Ann. Clin. Psychiatry, 6:67-78.
24. Scheffel, U., Szabo, Z., Mathews, W.B., Finley, P.A., Yuan, J., Callahan, B., Hatzidimitriou, G., Dannals, R.F., Ravert, H.T., and Ricaurte, G.A. (1996) Fenfluramine-induced loss of serotonin transporters in baboon brain visualized with PET. Synapse, 24, 395-398.
25. Schmidt, C.J., Ritter, J.K., Sonsalla, P.K., Hanson, G.R., and Gibb, J.W. (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther., 233:539-544.
26. Schuster, C.R., Lewis, M., and Seiden, L.S. (1986) Fenfluramine: Neurotoxicity. Psychopharmacol. Bull., 22:148-151.
27. Silverstone, T. (1992) Appetite suppressants. A review. Drugs, 43:820-836.
28. Weintraub, M.D., (1992) Long-term weight control study: Conclusions. Clin. Pharmacol. Ther., 51:642-646.
29. Weintraub, M.D., Hasday, J.D., Mushlin, A.I., and Lockwood, D.H. (1984) A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med., 144:1143-1148.
30. Weintraub, M.D., Sundaresan, P.R., Madan, M., Schuster, B., Balder, A., Lasagna, L., and Cox. C. (1992a) Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin. Pharmacol. Ther., 51:586-594.
31. Weintraub, M.D., Sundaresan, P.R., Schuster, B., Averbuch, M., Stein, E.C., and Byrne, L. (1992b) Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication. Clin. Pharmacol. Ther., 51:615-618.
32. Weintraub, M.D., Sundaresan, P.R., Schuster, B., Averbuch, M., Stein, E.C., Cox, C., and Byrne. L. (1992c) Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin. Pharmacol. Ther. 51:608-614.
33. Weintraub, M.D., Sundaresan, P.R., Schuster, B., Ginsberg, G., Madan, M., Balder, A., Stein, E.C., and Byrne, L. (1992d) Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin. Pharmacol. Ther. 51:595-601.
34. Weintraub, M.D., Sundaresan, P.R., Schuster, B., Moscucci, M., and Stein, B.C. (1992e) Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin. Pharmacol. Ther. 51:602-607.